Literature DB >> 15322487

HIV-1 subtype distribution and the problem of drug resistance.

Mark A Wainberg1.   

Abstract

Genetic diversity is a hallmark of HIV-1 infection with regard to the expansion of distinct viral subtypes (clades A, B, C, D, E, F, G, K, and O) in different geographical regions. Here, we discuss the issues of HIV-1 sensitivity to antiretroviral drugs and drug resistance in the context of HIV-1 subtype diversity. Virtually all available evidence suggests that all subtypes of HIV display similar sensitivity to antiviral drugs, but viruses from some subtypes or geographical regions may occasionally have a greater propensity to develop resistance against certain drugs than other viral variants. In some situations, the types of mutations associated with resistance may vary, as a result of subtle differences among subtypes with regard to the genetic code. This consideration notwithstanding, drug resistance is unlikely to become a more serious issue in developing than developed countries, and there is an urgency to make anti-HIV drugs available to all who are in need.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322487     DOI: 10.1097/00002030-200406003-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.

Authors:  Andrea Galli; Mary Kearney; Olga A Nikolaitchik; Sloane Yu; Mario P S Chin; Frank Maldarelli; John M Coffin; Vinay K Pathak; Wei-Shau Hu
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 3.  Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Authors:  Avanthi Raghavan; Dodie E Rimmelin; Kathleen V Fitch; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

4.  HIV subtypes in Scotland, 2000-2006.

Authors:  D L Yirrell; L Shaw; E Campbell; S M Burns; S O Cameron; D Goldberg
Journal:  Epidemiol Infect       Date:  2007-10-09       Impact factor: 2.451

5.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load.

Authors:  Orna Mor; Yael Gozlan; Marina Wax; Fernando Mileguir; Avia Rakovsky; Bina Noy; Ella Mendelson; Itzchak Levy
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

7.  Intra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 Nef.

Authors:  Eduardo O'Neill; Laura L Baugh; Vladimir A Novitsky; Myron E Essex; J Victor Garcia
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Proceedings from the NIMH symposium on "NeuroAIDS in Africa: neurological and neuropsychiatric complications of HIV".

Authors:  Shilpa Buch; Ernest T Chivero; Jackie Hoare; Jibreel Jumare; Noeline Nakasujja; Victor Mudenda; Robert Paul; Georgette D Kanmogne; Ned Sacktor; Charles Wood; Walter Royal; Jeymohan Joseph
Journal:  J Neurovirol       Date:  2016-07-29       Impact factor: 2.643

9.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

10.  Antiretroviral therapy: when to start and which drugs to use.

Authors:  Albert M Anderson; Jeffrey L Lennox
Journal:  Curr Infect Dis Rep       Date:  2008-07       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.